MREO News and Press, Mereo BioPharma Group From 05/30/24

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in...

2024-05-15 17:20:06 ET More on Mereo BioPharma Group Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities Mereo BioPharma Group GAAP EPS of -$0.04 Seeking Alpha’s Quant Rating on Mereo BioPharma Group Read the full article on Seeking...

2024-05-15 17:04:04 ET More on Mereo BioPharma Group Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities Mereo BioPharma Group GAAP EPS of -$0.04 Read the full article on Seeking Alpha For further details see: Mereo BioPharma Group GAAP ...

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and prov...

2024-04-10 04:08:49 ET Summary Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases and oncology treatments. Its flagship drugs include Setrusumab for Osteogenesis Imperfecta and Alvelestat for Alpha-1 Antitrypsin Deficiency. The company has s...

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...

2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...

2024-03-27 16:49:28 ET More on Mereo BioPharma Group Mereo BioPharma provides update on pipeline progress, reaffirms cash runway guidance Seeking Alpha’s Quant Rating on Mereo BioPharma Group Historical earnings data for Mereo BioPharma Group Financial...

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partn...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...